Elenestinib

Small molecule

Also known as BLU-263

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Phase 2/3underway

Evidence outlook · registrational

Systemic Mastocytosis: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2032-09-30.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Systemic Mastocytosis
NCT04910685 · Blueprint Medicines Corporation
2021-11-30 – 2032-09-30 · Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
What this study did
Phase 1 (2)
Systemic Mastocytosis
NCT05609942 · Blueprint Medicines Corporation
2023-09-25 – 2025-03-10 · Advanced Systemic Mastocytosis
What this study did
Other / comorbidity
NCT07388511 · Blueprint Medicines Corporation
2026-02-05 – 2026-04-02 · Healthy Participants
What this study did

Competitive landscape

This drug's own stage for Systemic Mastocytosis: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Elenestinib: this drugPhase 2/3Small moleculeKIT D816Vnot yet gradedNo reviewed efficacy summary in this indication
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRnot yet gradedNo reviewed efficacy summary in this indication
BezuclastinibPhase 2Small moleculeKITnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Elenestinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2032 (1)
September 2032 (1)
Phase 2/3Systemic MastocytosisRecruiting
Est. primary completion 2032-09-30 · NCT04910685 · CT.gov ↗
What to watch

See the full readout calendar ↗